Early detection is essential to improve the clinical outcomes for patients with cancerous brain tumours.

The BRAINED3 study focuses on assessing the performance of Infrared blood-based spectroscopy technology and its ability to identify patients suffering from non-specific symptoms who have a brain cancer.

The BRAINED3 study involves the collection of blood samples from two patient groups:

– Patients who are receiving diagnostic imaging to exclude brain cancer from their diagnosis

– Patients who have received a brain cancer diagnosis and who are yet to commence treatment

Integrating this technology into clinical pathways has the potential to identify high-risk patients who can then be prioritised for diagnostic imaging which could therefore allow for earlier brain cancer detection.

Status: active

Chief Investigator

Paul Brennan (PI)